Asset Details
Do you wish to reserve the book?
Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine
Do you wish to request the book?
Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine
2024
Overview
Group A Streptococcus (Strep A) causes both uncomplicated and severe invasive infections, as well as the post-infection complications acute rheumatic fever and rheumatic heart disease. Despite the high global burden of disease resulting from Strep A infections, there is not a licensed vaccine. A 30-valent M protein-based vaccine has previously been shown to be immunogenic in animal models and in a Phase I clinical trial (NCT02564237). Here, we assessed the immunogenicity of a 30-valent messenger (m)RNA vaccine designed to express the same M peptide targets as the 30-valent protein vaccine and compared it with the protein vaccine.
Female New Zealand white rabbits were immunized with one of four vaccine formulations (3 doses of each formulation at days 1, 28, and 56): soluble mRNA (100 μg/animal), C-terminal transmembrane mRNA (100 μg/animal), protein vaccine (400 μg/animal), or a non-translatable RNA control (100 μg/animal). Serum was collected one day prior to the first dose and on days 42 and 70. Rabbit serum samples were assayed for antibody levels against synthetic M peptides by ELISA. HL-60 opsonophagocytic killing (OPK) assays were performed to assess functional antibody levels.
Serum IgG levels were similar for the mRNA and protein vaccines. The CtTM version of the mRNA vaccine elicited slightly higher antibody levels than the mRNA designed to express soluble proteins. OPK activity was similar for the mRNA and protein vaccines, regardless of M type.
The total antibody responses and functional antibody levels elicited by the 30-valent mRNA Strep A vaccines were similar to those observed following immunization with the analogous protein vaccine. The mRNA vaccine platform provides potential advantages to protein-based vaccines including inherent adjuvant activity, increased production efficiency, lower cost, and the potential to rapidly change epitopes/peptides, all of which are important considerations related to multivalent Strep A vaccine development.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Animals
/ Antibodies, Bacterial - blood
/ Antibodies, Bacterial - immunology
/ Antigens
/ Antigens, Bacterial - genetics
/ Antigens, Bacterial - immunology
/ Bacteria
/ Bacterial Outer Membrane Proteins - genetics
/ Bacterial Outer Membrane Proteins - immunology
/ Carrier Proteins - immunology
/ Clinical Trials, Phase I as Topic
/ Design
/ Enzyme-linked immunosorbent assay
/ Epitopes
/ Ethanol
/ Female
/ females
/ fever
/ Lipids
/ mRNA
/ Peptides
/ Proteins
/ Rabbits
/ RNA
/ Software
/ Streptococcal Infections - immunology
/ Streptococcal Infections - prevention & control
/ Streptococcal Vaccines - administration & dosage
/ Streptococcal Vaccines - genetics
/ Streptococcal Vaccines - immunology
/ Streptococcus pyogenes - genetics
/ Streptococcus pyogenes - immunology
/ Vaccine
/ Vaccines
